New York, May 4, 2021 (GLOBE NEWSWIRE) – Reportlinker.com Announces Release of “Lung Cancer Drugs Global Market Report 2021: COVID 19 Impact and Recovery to 2030” – https://www.reportlinker.com/p06067909/?utm_source=GNW
06 billion in 2020 to $ 8.67 billion in 2021 at a compound annual growth rate (CAGR) of 7.6%. The growth is mainly due to the fact that the companies are rearranging their activities and recovering from the COVID-19 impact, which had previously led to restrictive measures related to social distance, remote working and the closure of commercial activities that resulted in operational challenges. The market is expected to hit $ 12.84 billion by 2025 at a CAGR of 10.3%.
The lung cancer drug market consists of the sale of lung cancer drugs. Lung cancer is a cancer that decreases the lung’s ability to deliver oxygen to the bloodstream due to uncontrolled growth of tissues in the lung.
Some of the possible treatments for lung cancer include surgery, chemotherapy, radiation therapy, and targeted therapy. Based on the size of the tumor cells, lung cancer is roughly divided into small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).
The FDA guidelines for lung cancer drugs are listed in Title Number 21 of the Code for Federal Regulations (CFR) under Part 312, which contains subsections from “A” to “I”. Section “E” deals with the procedures designed to stimulate the development, evaluation and marketing of drugs related to therapies intended for the treatment of individuals with life-threatening illnesses such as lung cancer.
The “E” subpart also provides guidelines for the monitoring and evaluation of clinical trials of lung cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing ones. these regulations by the FDA.
Hence, such regulations would also keep an eye on lung cancer drug manufacturers.
Targeted drug therapy in combination with other therapies is an emerging trend in the lung cancer market. It involves the use of immunotherapy drugs in combination with other therapies such as chemotherapy that aid in the early diagnosis, prevention and treatment of the disease.
In this regard, drug manufacturers are developing targeted drug therapies for better diagnosis and treatment of lung cancer. In 2018, Merck and Co. for example, pembrolizumab, a drug that helps the immune system detect and fight cancer cells when used alongside chemotherapy. This combination therapy showed an improvement in lung cancer status in patients. The drug is a major Merck and Co. product sold under the brand name Keytruda.
The rising prevalence of lung cancer is an important driver of the lung cancer market, mainly because an increase in the prevalence and incidence of lung cancer cases is driving the need for drugs that enable efficient and rapid treatment of the disease.
It also incentivizes the industry to maintain a strong pipeline of drugs. According to the International Agency for Research on Cancer (IARC), cancer resulted in approximately 9.6 million deaths in 2018, of which lung cancer was responsible for the largest number of deaths (1.8 million deaths, 18.4% of the total).
Increased use of biologics and targeted therapies is a major drag on the lung cancer market, as chemical drugs for lung cancer have numerous side effects and toxic effects on the body.
Chemical drugs lack cell specificity, ie they destroy even normal body cells along with cancer-infected cells. Although biologics are highly targeted and only work on cancer-infected cells. Organic drugs are also very efficient with no side effects. Clinical studies have also shown that biologics are much more likely to succeed than conventional chemical drugs. For example, Cetuximab, Gefitinib and Afatinib are biologics for lung cancer that specifically target the muffled form of tumors and do not destroy normal body cells.
Read the full report: https://www.reportlinker.com/p06067909/?utm_source=GNW
ReportLinker is an award-winning market research solution. Reportlinker searches and organizes the latest industry data, so you get all the market research you need right in one place.